Annual Dividends Capital Changes Warrants Shareholding Changes EPSDPSNTARevenueP/LQuarterQ DateFinancial YearAnnouncedROEQoQ%YoY%Report 31 Dec, 2024 19.0400 18.500 2.6317 3.1b 730.6m 4 2024-12-31 31 Dec, 2024 2025-02-25 7.2% 57.1% 68.5% View 12.1200 0.000 2.4351 2.9b 465.0m 3 2024-09-...
Verastem Oncology to present mature RAMP 201 data in low-grade serous ovarian cancer at the International Gynecologic Cancer Society 2024 Annual Meeting. Significant impact likely on future and performance due to potential presentation of key data at a major conference and ongoing clinical trials. 3...
Verastem, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024Mar. 20CI Verastem, Inc. Auditor Raises 'Going Concern' DoubtMar. 19CI Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Ca...
1. These figures are preliminary and are inherently uncertain due to a number of factors, and remain subject to review by the Company's management, audit committee and board of directors and the completion of regular financial closing and review procedures and audit procedures for Q4 FY2024 and...
and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review a detailed discussion of these risks, in Vision Marine's Annual Report on Form 20-F for the year ended August 31, 2024, and other periodic...
Every year, Essity publishes several Sustainability related publications, including our Annual report which contains sustainability information in accordance with the Global Reporting Initiative (GRI) guidelines for GRI Universal Standards. Read More
Join the community. Try Seeking Alpha for free by creating an account »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Account Account Login Manage My Portfolio Privacy Create Portfolio Portfolio Health Check Alert Preferences ...
This company is expected to earn $3.43 per share for the fiscal year ending December 2024, which represents a year-over-year change of 85.4%. Analysts have been steadily raising their estimates for TEMENOS GROUP. Over the past three months, the Zacks Consensus Estimate for the company has inc...
2024年6月1日,Kymera公布了KT-253的临床I期试验最新数据。KT-253在实体瘤和急性髓系白血病(AML)患者中获得了机制验证,显示出初步有效性,而且没有出现传统小分子抑制剂常有的血液学毒性,安全性和耐受性良好。 截至2024年4月9日,有24名患者参与试验,每3周一次KT-253静脉注射。A组有16名患者,患有复发/难治性...
We believeWTIoil prices would have to be sustained below $55/bbl for a matter of weeks for producers to curb activity (versus $62 on the morning of April 7). Incidentally, theU.S. oil rig counton Friday was the highest it’s been since June 2024 per Baker Hughes. Meanwhile, U.S....